Alan David Kaye

Dr. Alan David Kaye

LSU Hlth Sci Ctr, Dept Anesthesiol, Room 1-201, 1501 Kings Highway, Shreveport, LA, 71103, USA
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2021 in Neurology International
Verified
Journal Article
Open access
PDF file
AEAmber Edinoff
Amber Edinoff
HAHaseeb Akuly
Haseeb Akuly
THTony A. Hanna
Tony A. Hanna
COCarolina O. Ochoa
Carolina O. Ochoa
SPShelby J. Patti
Shelby J. Patti
Adam KayeAdam Kaye
Adam Kaye
Depression is the most prevalent psychiatric disorder in the world, affecting 4.4% of the global population. Despite an array of treatment modalities, depressive disorders remain difficult to manage due to many factors. Beginning with the introduction of fluoxetine to the United States in 1988, selective serotonin reuptake inhibitors (SSRIs) quickly became a mainstay of treatment for a variety of psychiatric disorders. The primary mechanism of action of SSRIs is to inhibit presynaptic reuptake of serotonin at the serotonin transporter, subsequently increasing serotonin at the postsynaptic membrane in the serotonergic synapse. The six major SSRIs that are marketed in the USA today, fluoxetine, citalopram, escitalopram, paroxetine, sertraline, and fluvoxamine, are a group of structurally unrelated molecules that share a similar mechanism of action. While their primary mechanism of action is similar, each SSRI has unique pharmacokinetics, pharmacodynamics, and side effect profile. One of the more controversial adverse effects of SSRIs is the black box warning for increased risk of suicidality in children and young adults aged 18–24. There is a lack of understanding of the complexities and interactions between SSRIs in the developing brain of a young person with depression. Adults, who do not have certain risk factors, which could be confounding factors, do not seem to carry this increased risk of suicidality. Ultimately, when prescribing SSRIs to any patient, a risk–benefit analysis must factor in the potential treatment effects, adverse effects, and dangers of the illness to be treated. The aim of this review is to educate clinicians on potential adverse effects of SSRIs.

10 November 2021 in Neurology International
Verified
Journal Article
Open access
PDF file
AEAmber N. Edinoff
Amber N. Edinoff
CNCatherine A. Nix
Catherine A. Nix
JHJanice Hollier
Janice Hollier
CSCaroline E. Sagrera
Caroline E. Sagrera
BDBlake Delacroix
Blake Delacroix
Alan David KayeAlan David Kaye
Alan David Kaye
Benzodiazepines (BZDs) are among one of the most widely prescribed drug classes in the United States. BZDs are a class of psychoactive drugs known for their depressant effect on the central nervous system (CNS). They quickly diffuse through the blood–brain barrier to affect the inhibitory neurotransmitter GABA and exert sedative effects. Related to their rapid onset and immediate symptom relief, BZDs are used for those struggling with sleep, anxiety, spasticity due to CNS pathology, muscle relaxation, and epilepsy. One of the debilitating side effects of BZDs is their addictive potential. The dependence on BZDs generally leads to withdrawal symptoms, requiring careful tapering of the medication when prescribed. Regular use of BZDs has been shown to cause severe, harmful psychological and physical dependence, leading to withdrawal symptoms similar to that of alcohol withdrawal. Some of these withdrawal symptoms can be life threatening. The current treatment for withdrawal is through tapering with clonazepam. Many drugs have been tested as a treatment for withdrawal, with few proving efficacious in randomized control trials. Future research is warranted for further exploration into alternative methods of treating BZD withdrawal. This call to action proves especially relevant, as those seeking treatment for BZD dependence and withdrawal are on the rise in the United States.

2 April 2020 in Current Pain and Headache Reports
Verified
Journal Article
Closed access
PDF file
Alan David KayeAlan David Kaye
Alan David Kaye
DCDavid J. Chernobylsky
David J. Chernobylsky
PTPankaj Thakur
Pankaj Thakur
HSHarish Siddaiah
Harish Siddaiah
RKRachel Kaye
Rachel Kaye
Elyse M. CornettElyse M. Cornett
Elyse M. Cornett

1 January 2012
Verified
Journal Article
Closed access
MFMichael Frass
Michael Frass
RSRobert Paul Strassl
Robert Paul Strassl
HFHelmut Friehs
Helmut Friehs
MMMichael Müllner
Michael Müllner
MKMichael Kundi
Michael Kundi
Alan David KayeAlan David Kaye
Alan David Kaye

28 January 2017 in Current Pain and Headache Reports
Verified
Journal Article
Closed access
PDF file
EHErik M. Helander
Erik M. Helander
BMBethany L. Menard
Bethany L. Menard
CHChris M. Harmon
Chris M. Harmon
BHBen K. Homra
Ben K. Homra
AAAlexander V. Allain
Alexander V. Allain
Alan David KayeAlan David Kaye
Alan David Kaye

15 February 2016 in Current Pain and Headache Reports
Verified
Journal Article
Closed access
PDF file
GHGraham R. Hadley
Graham R. Hadley
JGJulie A. Gayle
Julie A. Gayle
JRJuan Ripoll
Juan Ripoll
MJMark Jones
Mark Jones
CACharles E. Argoff
Charles E. Argoff
Alan David KayeAlan David Kaye
Alan David Kaye